IBDSF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where IBDSF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBDSF advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on IBDSF as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IBDSF turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBDSF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IBDSF entered a downward trend on November 22, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.372) is normal, around the industry mean (1.714). P/E Ratio (15.552) is within average values for comparable stocks, (23.466). Projected Growth (PEG Ratio) (3.597) is also within normal values, averaging (2.620). Dividend Yield (0.044) settles around the average of (0.074) among similar stocks. P/S Ratio (1.300) is also within normal values, averaging (3.109).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBDSF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry ElectricUtilities
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RSEGX | 59.02 | 0.68 | +1.17% |
Victory RS Small Cap Growth A | |||
CSXCX | 46.79 | 0.52 | +1.12% |
Calvert US Large Cap Core Rspnb Idx C | |||
BVSIX | 16.90 | 0.18 | +1.08% |
Baywood Socially Responsible Instl | |||
BNIEX | 9.92 | 0.04 | +0.40% |
UBS International Sustainable Equity A | |||
PHLQX | 44.13 | -4.82 | -9.84% |
PGIM Jennison Health Sciences R6 |
A.I.dvisor indicates that over the last year, IBDSF has been loosely correlated with IBDRY. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IBDSF jumps, then IBDRY could also see price increases.
Ticker / NAME | Correlation To IBDSF | 1D Price Change % | ||
---|---|---|---|---|
IBDSF | 100% | +0.91% | ||
IBDRY - IBDSF | 62% Loosely correlated | +1.40% | ||
EDPFY - IBDSF | 52% Loosely correlated | +0.78% | ||
ENLAY - IBDSF | 51% Loosely correlated | +1.00% | ||
EONGY - IBDSF | 45% Loosely correlated | +0.26% | ||
RDEIY - IBDSF | 44% Loosely correlated | +0.77% | ||
More |